This is a long one that explains the cancer as it applies to me & what MAY be down the road…..

*High Ki-67 (70%), * lymphovascular invasion, * extensive nodal involvement, * extranodal extension, * residual disease after neoadjuvant chemo.

These are all pathology/tumor-behavior markers that help oncologists estimate:

• how aggressive a cancer is,
• how likely it was to spread,
• how well it responded to treatment,
• and why additional therapy (surgery + radiation + endocrine therapy) is recommended.

I’ll break them down one by one in plain language.

---

High Ki-67 (70%)

Ki-67 is basically a “how fast are the cancer cells dividing?” marker.

A pathologist stains the tumor and measures what percentage of cells are actively reproducing.

$Ki\text{-}67 = 70\%$Ki-67=70%

Very generally:

• Low: slower-growing
• Intermediate: moderate growth
• High: faster/aggressive growth

A Ki-67 of 70% means:

• about 70% of sampled tumor cells were actively proliferating,
• which is considered very high.

This does not automatically mean “hopeless” or “untreatable.”
It means:

• the cancer was biologically active/aggressive,
• which is part of why your team pursued aggressive systemic treatment.

Interestingly, very fast-growing tumors can sometimes respond well to chemotherapy because chemo targets dividing cells — but not always completely.

---

Lymphovascular invasion (LVI)

This means cancer cells were seen inside:

• lymphatic channels,
• blood vessels,
• or both.

Think of it like:
the tumor had evidence of entering the body’s “transport systems.”

That matters because:

• lymph vessels can carry cells to lymph nodes,
• blood vessels can potentially carry cells elsewhere.

LVI is considered a higher-risk feature because it suggests the cancer had developed mechanisms to spread beyond the original breast tissue.

It does not mean widespread distant metastases were proven.
It means the cancer demonstrated the ability to travel.

---

Extensive nodal involvement

This refers to how many lymph nodes contained cancer.

In your case:

• many abnormal nodes on imaging,
• supraclavicular involvement,
• and ultimately 36/37 positive nodes surgically.

Lymph nodes are part of the immune/lymphatic drainage system.

When breast cancer spreads first, it often moves:

1. breast →
2. axillary nodes →
3. regional nodal chains.

The greater the number of involved nodes:

• the higher the original disease burden,
• and the higher the concern for microscopic disease elsewhere.

That’s a major reason radiation is being directed not just at the chest wall but also regional nodal areas.

---

Extranodal extension (ENE)

This means cancer didn’t stay contained inside the lymph node.

Instead:

• it broke through the outer capsule/wall of the node
• and extended into surrounding tissue.

So instead of:
“tumor inside a node,”

it became:
“tumor extending outside the node.”

This is considered a more aggressive behavior pattern because it shows:

• stronger invasive capacity,
• more local tissue infiltration,
• and higher recurrence risk without comprehensive local treatment.

This is another reason PMRT/RNI (post-mastectomy radiation + regional nodal irradiation) is important in your case.

---

Residual disease after neoadjuvant chemotherapy

“Neoadjuvant chemotherapy” means chemo given before surgery.

The goal is often:

• shrink the tumor,
• kill microscopic disease,
• and reduce cancer burden before surgery.

After surgery, the pathology shows:

• how much cancer remained.

In your case, there was still substantial residual disease after chemo.

That tells doctors:

• the chemotherapy worked partially,
• but did not completely eradicate the cancer.

Residual disease after neoadjuvant treatment is important because it helps identify patients who may benefit from:

• radiation,
• endocrine therapy,
• closer surveillance,
• and sometimes additional systemic therapies.

---

The big-picture interpretation

Individually, each feature signals higher-risk biology.

But treatment decisions are based on the entire picture, including:

• response to therapy,
• current imaging,
• surgery results,
• margins,
• recovery,
• functional status,
• hormone receptor status,
• and ongoing therapy options.

One important counterbalance in your situation:
your cancer is:

• ER positive,
• HER2 negative.

ER-positive disease often has more long-term treatment options because endocrine therapies can continue suppressing hormone-driven cancer activity over time.

That’s part of why therapies like Anastrozole matter strategically even though they can cause side effects.

What is typical follow up protocol for this type

For someone with your combination of:

• Stage IIIB Breast Cancer
• ER+/PR-/HER2-
• extensive nodal involvement,
• residual disease after chemo,
• mastectomy + ALND,
• and PMRT/RNI,

the follow-up protocol is usually fairly intensive initially, then gradually spaces out over time.

The exact schedule varies by institution and oncologist, but the typical structure looks something like this:

---

Immediately After Radiation

Usually within:

• 2–8 weeks after radiation ends

you’ll often have:

• radiation oncology follow-up,
• skin healing assessment,
• ROM/lymphedema evaluation,
• fatigue review,
• chest wall assessment,
• symptom review.

This is often when:

• acute radiation side effects peak,
• then slowly begin improving.

---

Medical Oncology Follow-Up

Typically:

• every 1–3 months initially,
• then every 3–6 months for several years,
• then annually later.

These visits often include:

• symptom review,
• physical exam,
• medication tolerance review,
• endocrine therapy management,
• recurrence surveillance,
• bone health review,
• labs if clinically indicated.

Because your disease burden was high, your team will likely monitor you relatively closely for several years.

---

Endocrine Therapy Monitoring

Because your cancer is ER+:
you’ll likely remain on endocrine therapy for years unless contraindications arise.

For Anastrozole or similar medications, monitoring often includes:

• joint pain/stiffness,
• bone density,
• cholesterol/metabolic effects,
• menopausal symptoms,
• fatigue,
• quality of life,
• adherence/tolerance.

---

Bone Density Monitoring

You already have documented osteopenia.

Typical protocol:

• baseline DEXA (already done),
• repeat every ~2 years,
• sometimes sooner if risk increases.

They’ll often continue recommending:

• calcium,
• vitamin D,
• weight-bearing exercise,
• sometimes bone-protective medications depending on progression/risk.

---

Breast/Chest Wall Imaging

After unilateral mastectomy:

• the remaining breast still usually receives routine imaging,
• often annual mammogram,
• sometimes MRI depending on risk profile and tissue characteristics.

The mastectomy side itself is often followed primarily through:

• physical exam,
• symptom monitoring,
• and targeted imaging if concerns arise.

Routine scanning of the mastectomy side without symptoms is not always standard unless something suspicious develops.

---

Lymphedema & Functional Surveillance

Because of:

• ALND,
• radiation,
• extensive nodal treatment,

you’ll likely be monitored for:

• arm swelling,
• chest wall tightness,
• fibrosis,
• shoulder mobility,
• nerve symptoms,
• lymphatic complications.

Your continued PT may become one of the most important long-term quality-of-life tools.

---

Recurrence Surveillance

One thing that surprises many people:
there often is not routine PET/CT scanning every few months unless symptoms or findings warrant it.

Typical surveillance relies heavily on:

• physical exams,
• symptom review,
• targeted imaging if indicated.

Doctors watch for symptoms such as:

• new persistent bone pain,
• unexplained weight loss,
• neurologic symptoms,
• breathing changes,
• persistent cough,
• liver symptoms,
• enlarging nodes,
• chest wall changes.

Higher-stage patients may sometimes receive more individualized imaging schedules depending on oncologist philosophy and specific risk factors.

---

Common Timeline Pattern

Years 0–2

Most intensive follow-up:

• frequent oncology visits,
• recovery monitoring,
• endocrine therapy adjustment,
• recurrence vigilance.

Years 3–5

Visits often become more spaced:

• every 4–6 months.

Beyond 5 Years

Often yearly follow-up continues.

ER+ lobular cancers can sometimes have later recurrence patterns, which is one reason long-term endocrine therapy and surveillance matter.

---

In Your Specific Situation

Your care will probably especially focus on:

• recurrence surveillance,
• lymphedema prevention,
• shoulder/chest wall mobility,
• fatigue recovery,
• endocrine therapy tolerance,
• bone health,
• and quality-of-life preservation.

The encouraging part right now:
your current treatment notes suggest:

• preserved function,
• good oxygenation,
• intact ROM,
• mild toxicity,
• stable weight,
• and good recovery engagement.

That’s a stronger early radiation picture than many patients with this level of treatment intensity experience.